Core Viewpoint - The company, Fangzhou Jianke, reported a revenue of 1.494 billion yuan for the first half of 2025, marking a year-on-year growth of 12.9%, and achieved a net profit of 12.5 million yuan, indicating a successful turnaround from losses [1][3][21]. Financial Performance - Revenue reached 1.494 billion yuan, up from 1.323 billion yuan [3] - Cost of sales was 1.225 billion yuan, compared to 1.057 billion yuan [3] - Gross profit stood at 268.3 million yuan, slightly up from 265.5 million yuan [3] - Adjusted net profit increased by 16.8% to 176 million yuan [1][3] User Engagement and Growth - The platform has 52.8 million registered users, with a monthly active user growth rate of 34.4% and a paid user repurchase rate of 85.4% [5][8]. - The high repurchase rate reflects strong user loyalty and the platform's effectiveness in chronic disease management [8]. Competitive Advantage - Fangzhou Jianke's core competitiveness lies in its H2H (Hospital-to-Home) smart healthcare ecosystem, which fosters long-term interactions between patients and healthcare providers [7]. - The platform has registered 229,000 doctors, with 58.9% from tertiary hospitals, enhancing user trust and engagement [8]. Service Experience and Supply Chain - The company improved its service experience by optimizing its app and mini-program, leading to a 28.2% increase in online retail pharmacy revenue to 864 million yuan [9]. - Prescription drugs accounted for 81.7% of total transaction value, highlighting the platform's focus on chronic disease management [9]. Market Dynamics and Policy Support - The aging population in China is driving demand for chronic disease management services, with over 310 million people aged 60 and above by the end of 2024 [17]. - Recent government policies support the integration of AI and big data in healthcare, providing a favorable environment for Fangzhou Jianke's growth [14][17]. Technological Integration - The company is advancing its "AI + Chronic Disease Management" strategy, utilizing AI tools to enhance service efficiency and patient management [19]. - AI-driven solutions have improved operational efficiency, with inventory turnover maintained at 25.7 days [19]. Valuation and Market Perception - Despite strong performance and competitive advantages, the company's market valuation remains low at approximately 5.2 billion yuan, not reflecting its potential in chronic disease management [21][22]. - The market's delayed recognition of the company's ecological value and AI integration strategy is seen as a key factor in the current valuation gap [22].